{"DataElement":{"publicId":"7028262","version":"1","preferredName":"Endometrial Carcinoma FIGO Histopathologic Grade","preferredDefinition":"The grade representing the extent of endometrial cancer in the body, based on staging criteria from the Federation of Gynecology and Obstetrics (FIGO).","longName":"EDMTR_FIGO_HX_GD","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"7027142","version":"1","preferredName":"Endometrial Carcinoma Federation of Gynecology and Obstetrics Histologic Grade","preferredDefinition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation._An international organization with a mission to promote the wellbeing of women and to raise the standards of practice in obstetrics and gynecology. They are the creator of staging criteria to describe the extent and spread of gynecologic malignancies._The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","longName":"3104218v1.0:7027140v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"3104218","version":"1","preferredName":"Endometrial Carcinoma","preferredDefinition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation. -- 2004","longName":"C7558","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial Carcinoma","conceptCode":"C7558","definition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87F3C580-07AC-1DC3-E040-BB89AD434E7E","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"ONEDATA","dateModified":"2010-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7027140","version":"1","preferredName":"Federation of Gynecology and Obstetrics Histologic Grade","preferredDefinition":"An international organization with a mission to promote the wellbeing of women and to raise the standards of practice in obstetrics and gynecology. They are the creator of staging criteria to describe the extent and spread of gynecologic malignancies.:The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","longName":"C89808:C18000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Federation of Gynecology and Obstetrics","conceptCode":"C89808","definition":"An international organization with a mission to promote the wellbeing of women and to raise the standards of practice in obstetrics and gynecology. They are the creator of staging criteria to describe the extent and spread of gynecologic malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95AC3360-B5CB-6EBA-E053-F662850ADF88","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95AC3360-B5DC-6EBA-E053-F662850ADF88","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"HARTLEYG","dateModified":"2019-10-30","changeDescription":"Curated to support Endometrial content_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7027572","version":"1","preferredName":"Histologic Grade","preferredDefinition":"A position on a scale of intensity or amount or quality.","longName":"7027572v1.0","context":"OCG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Cannot be assessed","valueDescription":"Grade X","ValueMeaning":{"publicId":"5210903","version":"1","preferredName":"Grade X","longName":"5210903","preferredDefinition":"A morphologic qualifier indicating that the grade of a neoplasm cannot be assessed.","context":"PMI","contextVersion":"1","Concepts":[{"longName":"Grade X","conceptCode":"C113730","definition":"A morphologic qualifier indicating that the grade of a neoplasm cannot be assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"2FC19F3A-FBBE-BEEA-E050-BB89AD436723","latestVersionIndicator":"Yes","beginDate":"2022-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-04-05","modifiedBy":"LISU","dateModified":"2022-08-05","changeDescription":null,"administrativeNotes":"8/5/2022: created for PMI EC form. SL","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95B27BB6-0771-6E37-E053-F662850AABC6","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","deletedIndicator":"No"},{"value":"Other (specify)","valueDescription":"Other","ValueMeaning":{"publicId":"5697874","version":"1","preferredName":"Other","longName":"5697874","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A253837-4DE2-5542-E053-F662850A338C","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-03-07","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95B27BB6-077B-6E37-E053-F662850AABC6","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5805854","version":"1","preferredName":"Not Applicable","longName":"5805854","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E9F04D2-6E6A-5FAB-E053-F662850A7FE5","latestVersionIndicator":"Yes","beginDate":"2017-05-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95B27BB6-0785-6E37-E053-F662850AABC6","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","deletedIndicator":"No"},{"value":"Grade 3","valueDescription":"Grade 3","ValueMeaning":{"publicId":"5622671","version":"1","preferredName":"Grade 3","longName":"5622671","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3","conceptCode":"C28079","definition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45D39BCC-34D0-6918-E053-F662850A008A","latestVersionIndicator":"Yes","beginDate":"2017-01-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95B27BB6-079A-6E37-E053-F662850AABC6","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","deletedIndicator":"No"},{"value":"Grade 2","valueDescription":"Grade 2","ValueMeaning":{"publicId":"5622672","version":"1","preferredName":"Grade 2","longName":"5622672","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is moderately differentiated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 2","conceptCode":"C28078","definition":"A morphologic qualifier indicating that a cancerous lesion is moderately differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45D39BCC-34F2-6918-E053-F662850A008A","latestVersionIndicator":"Yes","beginDate":"2017-01-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95B27BB6-07AF-6E37-E053-F662850AABC6","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","deletedIndicator":"No"},{"value":"Grade 1","valueDescription":"Grade 1","ValueMeaning":{"publicId":"3270009","version":"1","preferredName":"Grade 1","longName":"3270009","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is well differentiated.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 1","conceptCode":"C28077","definition":"A morphologic qualifier indicating that a cancerous lesion is well differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC4B0802-7E3A-C755-E040-BB89AD43108E","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95B27BB6-07C4-6E37-E053-F662850AABC6","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2453188","version":"1","preferredName":"Grade","preferredDefinition":"A position on a scale of intensity or amount or quality.","longName":"C48309","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"0DDD1E7C-BBFA-66D1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-28","modifiedBy":"ONEDATA","dateModified":"2006-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95B27BB6-0750-6E37-E053-F662850AABC6","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"HARTLEYG","dateModified":"2019-10-30","changeDescription":"Curated to support Endometrial content_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"7026248","version":"1","longName":"Endometrial","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"FIGO grade","type":"Preferred Question Text","description":"FIGO grade","url":null,"context":"OCG"}],"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95C30A7B-4FC1-3F74-E053-F662850A657F","latestVersionIndicator":"Yes","beginDate":"2019-10-25","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-25","modifiedBy":"HARTLEYG","dateModified":"2019-11-07","changeDescription":"Curated to support Endometrial content_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}